Show sidebar
Show 9 12 18 24
Compare
Quick view
Add to wishlist

Buy Darzalex (Daratumumab)

Price range: €395.00 through €1,185.00
Select options This product has multiple variants. The options may be chosen on the product page
Darzalex (Daratumumab) is a human, CD38-directed monoclonal antibody for the treatment of multiple myeloma.

Who is Darzalex (daratumumab) suitable for?

Darzalex (daratumumab) is indicated for patients with:

  • Newly diagnosed multiple myeloma for which autologous stem cell transplantation is not an option (first-line treatment). For this indication, it is used in combination with bortezomib, melphalan, and prednisone.

  • Patients with multiple myeloma who have received at least one prior therapy (second-line treatment). For this indication, it is used in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone.

  • Patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (third-line therapy). For this indication, it is used in combination with pomalidomide and dexamethasone.

  • Multiple myeloma patients who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are doubly refractory to a PI and an immunomodulatory agent (fourth-line treatment). For this indication, it is used as monotherapy.